Itraconazole alone versus with steroid pills for Aspergillus lung overlap
Part of Immune system & allergy, Infections, Lungs & breathing clinical trials.
This trial compares itraconazole taken by mouth alone versus itraconazole plus steroid pills in people who have a mix of two Aspergillus lung conditions. It aims to see which approach works better to control symptoms and lung changes caused by Aspergillus infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be diagnosed with both ABPA and CPA overlap based on specific blood tests and/or Aspergillus growth on breathing samples.
- Your symptoms must have lasted at least 3 months, such as cough, coughing blood, weight loss, fever, feeling unwell, or shortness of breath.
- Your chest CT scan must show long-lasting or slowly worsening lung findings like cavities, fibrosis, infiltrates, consolidation, fungal balls, or thickening of the lining around the lungs.
- You must not have other lung diseases that could explain your symptoms and scan results.
- You must not be taking certain immune-suppressing medicines or have taken prednisone (or similar) at high dose for at least 3 weeks.
- You must not be pregnant, and you should not have taken antifungal “triazole” pills for more than 3 weeks in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares three treatments for ABPA: a steroid (prednisolone), an antifungal (itraconazole), or both together. It aims to find which works best for controlling symptoms and preventing flare-ups.
This study compares two inhaled treatments (amphotericin B vs. saline) to see which one works better as maintenance therapy for people with chronic pulmonary aspergillosis. It aims to find a convenient way to keep the infection under control after initial treatment.
This study tests whether a combination of inhaled liposomal amphotericin B (Ambisome) plus itraconazole works better for chronic pulmonary aspergillosis (CPA). It may help control long-term Aspergillus lung infection and symptoms.
This study looks at how the presence of fungus in lung samples relates to the long-term outlook for people with allergic bronchopulmonary aspergillosis (ABPA). It aims to help doctors better understand the disease and guide treatment.
This trial tests a procedure that uses a bronchoscope to clean mucus from the airways and then spray the antifungal drug amphotericin B directly into the lungs. It may help people whose ABPA is active and not improving with standard treatments.
This study tests whether benralizumab, a biologic medicine, works well in real-world settings for people with severe asthma caused by an allergic reaction to a common mold called Aspergillus. You may qualify if you have hard-to-control asthma despite strong medications and recent asthma flare-ups.
Hear when a new Chronic Pulmonary Aspergillosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.